Literature DB >> 24491530

Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers.

Francesca Buttini1, Michele Miozzi2, Anna Giulia Balducci3, Paul G Royall4, Gaetano Brambilla5, Paolo Colombo2, Ruggero Bettini2, Ben Forbes4.   

Abstract

Solution composition alters the dynamics of beclomethasone diproprionate (BDP) particle formation from droplets emitted by pressurised metered dose inhalers (pMDIs). The hypothesis that differences in inhaler solutions result in different solid particle physical chemistry was tested using a suite of complementary calorimetric techniques. The atomisation of BDP-ethanol solutions from commercial HFA-pMDI produced aerodynamically-equivalent solid particle aerosols. However, differences in particle physico-chemistry (morphology and solvate/clathrate formation) were detected by differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and supported by hot stage microscopy (HSM). Increasing the ethanol content of the formulation from 8 to 12% (w/w), which retards the evaporation of propellant and slows the increase in droplet surface viscosity, enhanced the likelihood of particles drying with a smooth surface. The dissolution rate of BDP from the 12% (w/w) ethanol formulation-derived particles (63% dissolved over 120 min) was reduced compared to the 8% (w/w) ethanol formulation-derived particles (86% dissolved over 120 min). The addition of 0.01% (w/w) formoterol fumarate or 1.3% (w/w) glycerol to the inhaler solution modified the particles and reduced the BDP dissolution rate further to 34% and 16% dissolved in 120 min, respectively. These data provide evidence that therapeutic aerosols from apparently similar inhaler products, including those with similar aerodynamic performance, may behave non-equivalently after deposition in the lungs.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Beclomethasone dipropionate (BDP); Bioequivalence; Hydrofluoroalkane; Orally inhaled drug product (OIDP); Pressurised metered dose inhaler (pMDI)

Mesh:

Substances:

Year:  2014        PMID: 24491530     DOI: 10.1016/j.ijpharm.2014.01.033

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  17 in total

1.  Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Effects of Nasal Spray Suspension Particle Size and Properties.

Authors:  Alex Rygg; Michael Hindle; P Worth Longest
Journal:  Pharm Res       Date:  2015-12-21       Impact factor: 4.200

Review 2.  In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches.

Authors:  Ben Forbes; Per Bäckman; David Christopher; Myrna Dolovich; Bing V Li; Beth Morgan
Journal:  AAPS J       Date:  2015-05-05       Impact factor: 4.009

3.  Effects of the antibiotic component on in-vitro bacterial killing, physico-chemical properties, aerosolization and dissolution of a ternary-combinational inhalation powder formulation of antibiotics for pan-drug resistant Gram-negative lung infections.

Authors:  Sharad Mangal; Jiayang Huang; Nivedita Shetty; Heejun Park; Yu-Wei Lin; Heidi H Yu; Dmitry Zemlyanov; Tony Velkov; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2019-02-21       Impact factor: 5.875

4.  Small Airway Absorption and Microdosimetry of Inhaled Corticosteroid Particles after Deposition.

Authors:  P Worth Longest; Michael Hindle
Journal:  Pharm Res       Date:  2017-06-22       Impact factor: 4.200

5.  Accessorized DPI: a Shortcut towards Flexibility and Patient Adaptability in Dry Powder Inhalation.

Authors:  Francesca Buttini; James Hannon; Kristi Saavedra; Irene Rossi; Anna Giulia Balducci; Hugh Smyth; Andy Clark; Paolo Colombo
Journal:  Pharm Res       Date:  2016-09-13       Impact factor: 4.200

6.  Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol.

Authors:  Paul Zarogoulidis; Ioannis Kioumis; Sofia Lampaki; John Organtzis; Konstantinos Porpodis; Dionysios Spyratos; Georgia Pitsiou; Dimitris Petridis; Athanasia Pataka; Haidong Huang; Qiang Li; Lonny Yarmus; Wolfgang Hohenforst-Schmidt; Nikolaos Pezirkianidis; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2014-08-12       Impact factor: 4.162

7.  Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.

Authors:  Georgia Pitsiou; Paul Zarogoulidis; Dimitris Petridis; Ioannis Kioumis; Sofia Lampaki; John Organtzis; Konstantinos Porpodis; Antonis Papaiwannou; Theodora Tsiouda; Wolfgang Hohenforst-Schmidt; Stylianos Kakolyris; Konstantinos Syrigos; Haidong Huang; Qiang Li; J Francis Turner; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2014-10-07       Impact factor: 4.162

8.  Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Development of a CFD Model.

Authors:  Alex Rygg; P Worth Longest
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-01-29       Impact factor: 2.849

Review 9.  Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT).

Authors:  Mark L Levy; P N R Dekhuijzen; P J Barnes; M Broeders; C J Corrigan; B L Chawes; L Corbetta; J C Dubus; Th Hausen; F Lavorini; N Roche; J Sanchis; Omar S Usmani; J Viejo; W Vincken; Th Voshaar; G K Crompton; Soren Pedersen
Journal:  NPJ Prim Care Respir Med       Date:  2016-04-21       Impact factor: 2.871

10.  Multivariate Analysis of Effects of Asthmatic Patient Respiratory Profiles on the In Vitro Performance of a Reservoir Multidose and a Capsule-Based Dry Powder Inhaler.

Authors:  Francesca Buttini; Irene Pasquali; Gaetano Brambilla; Diego Copelli; Massimiliano Dagli Alberi; Anna Giulia Balducci; Ruggero Bettini; Viviana Sisti
Journal:  Pharm Res       Date:  2015-11-16       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.